{"nctId":"NCT02617485","briefTitle":"MabionCD20 Compared to MabThera in Lymphoma Patients","startDateStruct":{"date":"2015-12","type":"ACTUAL"},"conditions":["Diffuse Large B-Cell Lymphoma"],"count":143,"armGroups":[{"label":"MabionCD20","type":"EXPERIMENTAL","interventionNames":["Drug: Rituximab","Drug: Doxorubicin","Drug: Vincristine","Drug: Cyclophosphamide","Drug: prednisone"]},{"label":"MabThera","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Rituximab","Drug: Doxorubicin","Drug: Vincristine","Drug: Cyclophosphamide","Drug: prednisone"]}],"interventions":[{"name":"Rituximab","otherNames":["MabThera®, MabionCD20®"]},{"name":"Doxorubicin","otherNames":["Hydroxydaunorubicin"]},{"name":"Vincristine","otherNames":["Oncovine"]},{"name":"Cyclophosphamide","otherNames":[]},{"name":"prednisone","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patients with histological confirmed CD20 (cluster of differentiation 20) positive diffuse large B cell lymphoma (DLBCL)\n2. Patients that had been diagnosed according to the WHO classification;\n3. Performance status ≤ 2 on the ECOG (Eastern Cooperative Oncology Group) / WHO (world Health Organization) scale, performance status of 3 will be accepted if impairment is caused by DLBCL complications and improvement is expected once therapy is initiated;\n\nExclusion Criteria:\n\n1. Life expectance less than 6 months;\n2. Any chemotherapy, radiotherapy, immunotherapy, biologic, investigational or hormonal therapy for treatment of lymphoma within 28 days prior to treatment;\n3. Rituximab, other anti-CD20 mAb (Monoclonal Antibodies) drug treatment, treatment with any cell depleting therapies - e.g., anti-CD4 (cluster of differentiation 4) anti-CD5 (cluster of differentiation 5), anti-CD3 (cluster of differentiation 3), anti-CD19 (cluster of differentiation 19), anti CD11 (cluster of differentiation 11), anti-CD22 (cluster of differentiation 11), BLys/BAFF (B Lymphocyte Stimulator/B-cell activating factor) within 1,5 years before screening;","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Area Under the Serum Concentration-time Curve From Day 1 to Week 4 (AUC[1-4])","description":"Area under the serum concentration-time curve from time zero (Day 1) to final time point measured after the first administration (Week 1) until Week 4 (AUC(W1-W4)). PK blood samples for this endpoint were drawn at Day 1 (before and after the first infusion), Day 8 ± 1 (7 days after first infusion), Day 15 ± 1 (14 days after first infusion), Day 22 ± 2 (before and after completion of the second infusion).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1559.51","spread":"358.092"},{"groupId":"OG001","value":"1509.79","spread":"382.559"}]}]}]},{"type":"PRIMARY","title":"Area Under the Serum Concentration-time Curve From Week 13 to Week 26 (AUC[W13-W26])","description":"Area under the serum concentration-time curve from time zero to final time point measured from Week 13 until Week 26 (AUC\\[W13-W26\\]). PK blood samples for this endpoint were drawn at Day 85 ± 4 (before and after completion of the fifth infusion), Day 106 ± 4 (before and after completion of sixth infusion), Day 127 ± 4 (before and after completion of the seventh infusion), Day 148 ± 4 (before and after completion of the eight infusion), Day 155 ± 4 (one week after last infusion) and Day 176 ± 4 (one month after last infusion).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16498.9","spread":"3492.39"},{"groupId":"OG001","value":"15647.4","spread":"3629.83"}]}]}]},{"type":"SECONDARY","title":"Ctrough (Before 8th Infusion)","description":"Trough serum concentration measured at the end of a dosing interval at steady state, taken directly before eighth infusion.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"102.246","spread":"43.897"},{"groupId":"OG001","value":"90.61","spread":"41.994"}]}]}]},{"type":"SECONDARY","title":"Cmax (Post 5th and 8th Infusion)","description":"Maximum serum drug concentration (Cmax) at steady state after the 5th and 8th infusions.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"273.356","spread":"65.452"},{"groupId":"OG001","value":"266.439","spread":"66.086"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"296.784","spread":"58.295"},{"groupId":"OG001","value":"296.462","spread":"69.641"}]}]}]},{"type":"SECONDARY","title":"Kel (Post 5th and 8th Infusions)","description":"Elimination Rate Constant at steady stade after the 5th and 8th infusions.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05663","spread":"0.01794"},{"groupId":"OG001","value":"0.05418","spread":"0.01884"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04335","spread":"0.01528"},{"groupId":"OG001","value":"0.04379","spread":"0.0123"}]}]}]},{"type":"SECONDARY","title":"T1/2 (Post 5th and 8th Infusions)","description":"Elimination half-life at steady state after the 5th and 8th infusions.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.801","spread":"12.218"},{"groupId":"OG001","value":"15.217","spread":"7.889"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.301","spread":"7.92"},{"groupId":"OG001","value":"16.997","spread":"4.515"}]}]}]},{"type":"SECONDARY","title":"CLss (Post 5th and 8th Infusions)","description":"Clearance at steady state after the 5th and 8th infusions.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"198.701","spread":"53.427"},{"groupId":"OG001","value":"206.905","spread":"78.213"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"179.168","spread":"58.509"},{"groupId":"OG001","value":"191.272","spread":"89.016"}]}]}]},{"type":"SECONDARY","title":"AUC (W1-W26) B-cell","description":"Area under the serum concentration-time curve of CD19+ B cell counts, measured from the first administration to the final time point at Week 26 (AUC(1-26) B-cell).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3395.82","spread":"22364.5"},{"groupId":"OG001","value":"10476.2","spread":"56943.0"}]}]}]},{"type":"SECONDARY","title":"AUC (W1-W26)","description":"Area under the serum concentration-time curve measured after the first administration (Week 1) until Week 26 (AUC(1-26))","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28413.6","spread":"5194.98"},{"groupId":"OG001","value":"26955.3","spread":"5849.22"}]}]}]},{"type":"SECONDARY","title":"Efficacy Assessment at Week 26","description":"An efficacy assessment was made after 8 treatment cycles (at Week 26) based on tumour responses classified according to the International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (Cheson et al. 1999). Response was assessed based on clinical, radiologic (CT scan) and pathologic (bone marrow) criteria. Possible efficacy responses were: complete response, partial response, stable disease, and progressive disease. Efficacy reported here includes all patients included in the ITT set.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Adverse Events","description":"Percentage of patients with at least one AE in a given category. Data from the entire follow-up are included (Period 1 and Period 2).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.0","spread":null},{"groupId":"OG001","value":"67.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.0","spread":null},{"groupId":"OG001","value":"65.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.0","spread":null},{"groupId":"OG001","value":"12.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.0","spread":null},{"groupId":"OG001","value":"22.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.0","spread":null},{"groupId":"OG001","value":"42.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.0","spread":null},{"groupId":"OG001","value":"22.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":null},{"groupId":"OG001","value":"5.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Immunogenicity","description":"Percentage of patients with positive ADA or NAb results in a given category. Data pertain to the entire follow-up period (from Baseline to Week 46).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":19,"n":100},"commonTop":["Neutropenia","Leukopenia","Alopecia","Anaemia","White blood count decreased"]}}}